Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28965585 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL2941289 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL3980817 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL503890 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL2185289 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL11271012 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL11275301 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL8029516 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL503511 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH | |
| SCHEMBL2150291 | 1.00 | PPARD (0.54) | PPARDLPAR3LPAR2TSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119139479-A | Compositions comprising taxane nanoparticles and uses thereof | DFB索里亚有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118948828-A | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118649239-A | Topical delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | 克里蒂泰克公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-114588270-B | Compositions comprising taxane nanoparticles and uses thereof | DFB索里亚有限责任公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-110636833-B | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040023841-A1 | Combinatorial method for rapid screening of drug delivery formulations | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-02-05 | — | — | US | disclosed |
| EP-1105088-A4 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | SKINNOVATIVE DERMATOLOGIC CONC (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002016941-A2 | A COMBINATORIAL METHOD FOR RAPID SCREENING OF DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-1105088-A1 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | Skinnovative Dermatologic Concepts, L.L.C. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6217852-B1 | APPLYING DURING WASHING; SUNSCREEN AGENT | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. | 2001-04-17 | — | — | US | disclosed |
| WO-2000009081-A1 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. (US) | 2000-02-24 | — | — | WO | disclosed |
| US-4356097-A | Alkylphosphonate lubricating oil | EDWIN COOPER, INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4069247-A | Preparation of phosphonic and/or phosphinic acids | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | PPARD 2358/4885LPAR3 1494/4885LPAR2 1311/4885 |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | PPARD 1227/4885LPAR3 1919/4885LPAR2 1495/4885 |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | PPARD 2358/4885LPAR3 1494/4885LPAR2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.